Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 2002 Aug;57(8):694–700. doi: 10.1136/thorax.57.8.694

Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness

G Verhoeven 1, J Hegmans 1, P Mulder 1, J Bogaard 1, H Hoogsteden 1, J Prins 1
PMCID: PMC1746396  PMID: 12149529

Abstract

Background: Treatment of chronic obstructive pulmonary disease (COPD) with inhaled corticosteroids does not appear to be as effective as similar treatment of asthma. It seems that only certain subgroups of patients with COPD benefit from steroid treatment. A study was undertaken to examine whether inhaled fluticasone propionate (FP) had an effect on lung function and on indices of inflammation in a subgroup of COPD patients with bronchial hyperresponsiveness (BHR).

Methods: Twenty three patients with COPD were studied. Patients had to be persistent current smokers between 40 and 70 years of age. Non-specific BHR was defined as a PC20 for histamine of ≤8 mg/ml. Patients received either 2 x 500 µg FP or placebo for 6 months. Expiratory volumes were measured at monthly visits, BHR was determined at the start of the study and after 3 and 6 months, and bronchial biopsy specimens were taken at the start and after 6 months of treatment. Biopsy specimens from asymptomatic smokers served as controls.

Results: In contrast to asthma, indices of BHR were not significantly influenced by treatment with FP. Forced expiratory volume in 1 second (FEV1) showed a steep decline in the placebo group but remained stable in patients treated with FP. FEV1/FVC, and maximal expiratory flows at 50% and 25% FVC (MEF50, MEF25) were significantly increased in the FP treated patients compared with the placebo group. Biopsy specimens were analysed for the presence of CD3+, CD4+, CD8+, MBP+, CD15+, CD68+, CD1a, and tryptase cells. FP treatment resulted in marginal reductions in these indices of inflammation.

Conclusion: In patients with COPD and BHR, FP has a positive effect on indices of lung function compared with placebo. Bronchial inflammation analysed in bronchial biopsy specimens is only marginally reduced.

Full Text

The Full Text of this article is available as a PDF (204.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aerts J. G., Bogaard J. M., Overbeek S. E., Verbraak A. F., Thio P. Extrapolation of methacholine log-dose response curves with a Cumulative Gaussian Distribution function. Eur Respir J. 1994 May;7(5):895–900. [PubMed] [Google Scholar]
  2. Auffarth B., Postma D. S., de Monchy J. G., van der Mark T. W., Boorsma M., Koëter G. H. Effects of inhaled budesonide on spirometric values, reversibility, airway responsiveness, and cough threshold in smokers with chronic obstructive lung disease. Thorax. 1991 May;46(5):372–377. doi: 10.1136/thx.46.5.372. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brightling C. E., Monteiro W., Ward R., Parker D., Morgan M. D., Wardlaw A. J., Pavord I. D. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2000 Oct 28;356(9240):1480–1485. doi: 10.1016/S0140-6736(00)02872-5. [DOI] [PubMed] [Google Scholar]
  4. Burge P. S., Calverley P. M., Jones P. W., Spencer S., Anderson J. A., Maslen T. K. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000 May 13;320(7245):1297–1303. doi: 10.1136/bmj.320.7245.1297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chanez P., Vignola A. M., O'Shaugnessy T., Enander I., Li D., Jeffery P. K., Bousquet J. Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med. 1997 May;155(5):1529–1534. doi: 10.1164/ajrccm.155.5.9154853. [DOI] [PubMed] [Google Scholar]
  6. Corrigan C. J., Haczku A., Gemou-Engesaeth V., Doi S., Kikuchi Y., Takatsu K., Durham S. R., Kay A. B. CD4 T-lymphocyte activation in asthma is accompanied by increased serum concentrations of interleukin-5. Effect of glucocorticoid therapy. Am Rev Respir Dis. 1993 Mar;147(3):540–547. doi: 10.1164/ajrccm/147.3.540. [DOI] [PubMed] [Google Scholar]
  7. Engel T., Heinig J. H., Madsen O., Hansen M., Weeke E. R. A trial of inhaled budesonide on airway responsiveness in smokers with chronic bronchitis. Eur Respir J. 1989 Nov;2(10):935–939. [PubMed] [Google Scholar]
  8. Fabbri L., Caramori G., Beghe B., Papi A., Ciaccia A. Chronic obstructive pulmonary disease international guidelines. Curr Opin Pulm Med. 1998 Mar;4(2):76–84. doi: 10.1097/00063198-199803000-00004. [DOI] [PubMed] [Google Scholar]
  9. Finkelstein R., Ma H. D., Ghezzo H., Whittaker K., Fraser R. S., Cosio M. G. Morphometry of small airways in smokers and its relationship to emphysema type and hyperresponsiveness. Am J Respir Crit Care Med. 1995 Jul;152(1):267–276. doi: 10.1164/ajrccm.152.1.7599834. [DOI] [PubMed] [Google Scholar]
  10. Keatings V. M., Jatakanon A., Worsdell Y. M., Barnes P. J. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med. 1997 Feb;155(2):542–548. doi: 10.1164/ajrccm.155.2.9032192. [DOI] [PubMed] [Google Scholar]
  11. Kerstjens H. A., Brand P. L., Postma D. S. Risk factors for accelerated decline among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996 Dec;154(6 Pt 2):S266–S272. doi: 10.1164/ajrccm/154.6_Pt_2.S266. [DOI] [PubMed] [Google Scholar]
  12. Kerstjens H. A., Overbeek S. E., Schouten J. P., Brand P. L., Postma D. S. Airways hyperresponsiveness, bronchodilator response, allergy and smoking predict improvement in FEV1 during long-term inhaled corticosteroid treatment. Dutch CNSLD Study Group. Eur Respir J. 1993 Jun;6(6):868–876. [PubMed] [Google Scholar]
  13. Lamberts S. W., Koper J. W., Biemond P., den Holder F. H., de Jong F. H. Cortisol receptor resistance: the variability of its clinical presentation and response to treatment. J Clin Endocrinol Metab. 1992 Feb;74(2):313–321. doi: 10.1210/jcem.74.2.1309833. [DOI] [PubMed] [Google Scholar]
  14. Matsumoto K., Aizawa H., Inoue H., Koto H., Takata S., Shigyo M., Nakano H., Hara N. Eosinophilic airway inflammation induced by repeated exposure to cigarette smoke. Eur Respir J. 1998 Aug;12(2):387–394. doi: 10.1183/09031936.98.12020387. [DOI] [PubMed] [Google Scholar]
  15. Möller G. M., Overbeek S. E., van Helden-Meeuwsen C. G., Hoogsteden H. C., Bogaard J. M. Eosinophils in the bronchial mucosa in relation to methacholine dose-response curves in atopic asthma. J Appl Physiol (1985) 1999 Apr;86(4):1352–1356. doi: 10.1152/jappl.1999.86.4.1352. [DOI] [PubMed] [Google Scholar]
  16. Nagai A., Thurlbeck W. M., Konno K. Responsiveness and variability of airflow obstruction in chronic obstructive pulmonary disease. Clinicopathologic correlative studies. Am J Respir Crit Care Med. 1995 Mar;151(3 Pt 1):635–639. doi: 10.1164/ajrccm/151.3_Pt_1.635. [DOI] [PubMed] [Google Scholar]
  17. Niewoehner D. E., Erbland M. L., Deupree R. H., Collins D., Gross N. J., Light R. W., Anderson P., Morgan N. A. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med. 1999 Jun 24;340(25):1941–1947. doi: 10.1056/NEJM199906243402502. [DOI] [PubMed] [Google Scholar]
  18. O'Shaughnessy T. C., Ansari T. W., Barnes N. C., Jeffery P. K. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med. 1997 Mar;155(3):852–857. doi: 10.1164/ajrccm.155.3.9117016. [DOI] [PubMed] [Google Scholar]
  19. Overbeek S. E., Rijnbeek P. R., Vons C., Mulder P. G., Hoogsteden H. C., Bogaard J. M. Effects of fluticasone propionate on methacholine dose-response curves in nonsmoking atopic asthmatics. Eur Respir J. 1996 Nov;9(11):2256–2262. doi: 10.1183/09031936.96.09112256. [DOI] [PubMed] [Google Scholar]
  20. Paggiaro P. L., Dahle R., Bakran I., Frith L., Hollingworth K., Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet. 1998 Mar 14;351(9105):773–780. doi: 10.1016/s0140-6736(97)03471-5. [DOI] [PubMed] [Google Scholar]
  21. Pauwels R. A., Löfdahl C. G., Laitinen L. A., Schouten J. P., Postma D. S., Pride N. B., Ohlsson S. V. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med. 1999 Jun 24;340(25):1948–1953. doi: 10.1056/NEJM199906243402503. [DOI] [PubMed] [Google Scholar]
  22. Pesci A., Balbi B., Majori M., Cacciani G., Bertacco S., Alciato P., Donner C. F. Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. Eur Respir J. 1998 Aug;12(2):380–386. doi: 10.1183/09031936.98.12020380. [DOI] [PubMed] [Google Scholar]
  23. Postma D. S., Peters I., Steenhuis E. J., Sluiter H. J. Moderately severe chronic airflow obstruction. Can corticosteroids slow down obstruction? Eur Respir J. 1988 Jan;1(1):22–26. [PubMed] [Google Scholar]
  24. Riess A., Wiggs B., Verburgt L., Wright J. L., Hogg J. C., Paré P. D. Morphologic determinants of airway responsiveness in chronic smokers. Am J Respir Crit Care Med. 1996 Nov;154(5):1444–1449. doi: 10.1164/ajrccm.154.5.8912762. [DOI] [PubMed] [Google Scholar]
  25. Rijcken B., Schouten J. P., Xu X., Rosner B., Weiss S. T. Airway hyperresponsiveness to histamine associated with accelerated decline in FEV1. Am J Respir Crit Care Med. 1995 May;151(5):1377–1382. doi: 10.1164/ajrccm.151.5.7735588. [DOI] [PubMed] [Google Scholar]
  26. Saetta M. Airway inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 2):S17–S20. doi: 10.1164/ajrccm.160.supplement_1.6. [DOI] [PubMed] [Google Scholar]
  27. Syed F., Bingham B., Johnson M., Markham A. F., Morrison J. F. The CD4+ T lymphocyte is a site of steroid resistance in asthma. QJM. 1998 Aug;91(8):567–572. doi: 10.1093/qjmed/91.8.567. [DOI] [PubMed] [Google Scholar]
  28. Tashkin D. P., Altose M. D., Bleecker E. R., Connett J. E., Kanner R. E., Lee W. W., Wise R. The lung health study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. The Lung Health Study Research Group. Am Rev Respir Dis. 1992 Feb;145(2 Pt 1):301–310. doi: 10.1164/ajrccm/145.2_Pt_1.301. [DOI] [PubMed] [Google Scholar]
  29. Tashkin D. P., Altose M. D., Connett J. E., Kanner R. E., Lee W. W., Wise R. A. Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group. Am J Respir Crit Care Med. 1996 Jun;153(6 Pt 1):1802–1811. doi: 10.1164/ajrccm.153.6.8665038. [DOI] [PubMed] [Google Scholar]
  30. Taylor R. G., Joyce H., Gross E., Holland F., Pride N. B. Bronchial reactivity to inhaled histamine and annual rate of decline in FEV1 in male smokers and ex-smokers. Thorax. 1985 Jan;40(1):9–16. doi: 10.1136/thx.40.1.9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Vestbo J., Sørensen T., Lange P., Brix A., Torre P., Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 1999 May 29;353(9167):1819–1823. doi: 10.1016/s0140-6736(98)10019-3. [DOI] [PubMed] [Google Scholar]
  32. Watson A., Lim T. K., Joyce H., Pride N. B. Failure of inhaled corticosteroids to modify bronchoconstrictor or bronchodilator responsiveness in middle-aged smokers with mild airflow obstruction. Chest. 1992 Feb;101(2):350–355. doi: 10.1378/chest.101.2.350. [DOI] [PubMed] [Google Scholar]
  33. Weiner P., Weiner M., Rabner M., Waizman J., Magadle R., Zamir D. The response to inhaled and oral steroids in patients with stable chronic obstructive pulmonary disease. J Intern Med. 1999 Jan;245(1):83–89. doi: 10.1046/j.1365-2796.1999.00412.x. [DOI] [PubMed] [Google Scholar]
  34. Woolcock A. J., Anderson S. D., Peat J. K., Du Toit J. I., Zhang Y. G., Smith C. M., Salome C. M. Characteristics of bronchial hyperresponsiveness in chronic obstructive pulmonary disease and in asthma. Am Rev Respir Dis. 1991 Jun;143(6):1438–1443. doi: 10.1164/ajrccm/143.6.1438. [DOI] [PubMed] [Google Scholar]
  35. van Grunsven P. M., van Schayck C. P., Derenne J. P., Kerstjens H. A., Renkema T. E., Postma D. S., Similowski T., Akkermans R. P., Pasker-de Jong P. C., Dekhuijzen P. N. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax. 1999 Jan;54(1):7–14. doi: 10.1136/thx.54.1.7. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES